Summit Street Capital Management LLC Purchases New Holdings in Lantheus Holdings, Inc. $LNTH

Summit Street Capital Management LLC acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 400,699 shares of the medical equipment provider’s stock, valued at approximately $44,454,000. Lantheus makes up 6.2% of Summit Street Capital Management LLC’s holdings, making the stock its largest position. Summit Street Capital Management LLC owned 0.61% of Lantheus at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in LNTH. Jupiter Topco LLC acquired a new position in Lantheus in the 2nd quarter valued at $575,628,000. ABS Investment Management LLC purchased a new stake in shares of Lantheus during the second quarter worth $232,974,000. Hsbc Holdings PLC purchased a new stake in shares of Lantheus during the second quarter worth $2,273,000. EFG International AG acquired a new stake in shares of Lantheus in the second quarter valued at about $100,000. Finally, Expect Equity LLC acquired a new stake in shares of Lantheus in the second quarter valued at about $3,558,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LNTH. Brookline Capital Markets lowered shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Mizuho lowered their target price on Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Wednesday, July 29th. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Finally, Leerink Partners set a $102.50 price objective on Lantheus in a research note on Monday, August 3rd. Four equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $108.11.

Lantheus Price Performance

LNTH stock opened at $100.82 on Thursday. Lantheus Holdings, Inc. has a 52-week low of $49.67 and a 52-week high of $111.86. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. The stock has a market cap of $6.58 billion, a price-to-earnings ratio of 24.35 and a beta of -0.03. The business has a fifty day moving average of $103.87 and a two-hundred day moving average of $91.26.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating the consensus estimate of $1.30 by $0.25. The business had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.57 EPS. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.